12:00 AM
 | 
Nov 15, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Pimagedine aminoguanidine: Phase III data

Final data from ALTN's 690-patient North American ACTION I trial showed that pimagedine treatment reduced total urinary protein excretion (p<0.001 versus placebo) and reduced the number of patients with a doubling...

Read the full 133 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >